StreetSmart Live! Presents Michael Ballanger on 10/26/2020. Learn More

Streetwise Reports' Article Archives — August 2020 back to current month (32)

Aimmune Therapeutics Shares Soar on Nestlé Health Science's $2.6 Billion Buyout (08/31/2020)

Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash.

more>

Firm Submits Clinical Protocol for IRB Approval for Phase 3 COVID-19 Trial (08/28/2020)

Revive Therapeutics reported it submitted the clinical protocol for independent Institutional Review Board approval for its Phase 3 study of Bucillamine in COVID-19.

more>

VBI Shares Climb 34% After Identifying Two One-Dose COVID-19 Vaccine Candidates (08/27/2020)

VBI Vaccines shares traded higher after the company reported preclinical coronavirus program data and selection of clinical candidates with potential as one-dose vaccines.

more>

Firm's Home Health Monitoring System Provides the 'Most Comprehensive Offering in the Telehealth Space' (08/26/2020)

As the Covid pandemic accelerates the adoption of telemedicine technology, Reliq Health Technologies' recent contracts represent exponential growth.

more>

Fluidigm Shares Climb 34% After FDA Authorizes Saliva-Based COVID-19 Test (08/26/2020)

Fluidigm Corp. shares reached a new 52-week high after the firm reported the FDA granted Emergency Use Authorization for saliva-based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19.

more>

CytoDyn Receives the UK's MHRA Approval for Phase 3 COVID-19 Study (08/24/2020)

CytoDyn Inc. shares traded higher after the company reported it received authorization from the U.K.'s MHRA to proceed with its Phase 3 study of leronlimab in patients with severe-to-critical COVID-19.

more>

Cryoport to Acquire CRYOPDP for €49 Million to Expand Global Supply Chain (08/21/2020)

Shares of Cryoport Inc. reached a new 52-week high after the company reported it signed an agreement to acquire French firm CRYOPDP in an all cash transaction valued at €49 million.

more>

CureVac Shares Rise on Talks with EC to Supply 405 Million mRNA-Based COVID-19 Vaccine Doses (08/20/2020)

CureVac NV shares traded 13% higher after the company reported it is in advanced discussions with the European Commission to supply up to 405 million doses of a potential mRNA-based COVID-19 vaccine.

more>

Biotech Releases Positive Interim Results from Cystic Fibrosis Study (08/19/2020)

This and other recent key events of AzurRx BioPharma are recapped in a ROTH Capital Partners report.

more>

California Biopharma to be Acquired by Sanofi for $3.6 Billion (08/19/2020)

The deal is summarized and Principia Biopharma's Q2/20 clinical achievements are recapped in an H.C. Wainwright & Co. report.

more>

Momenta Pharmaceuticals Shares Rise 69% on $6.5 Billion Johnson & Johnson Takeover Bid (08/19/2020)

Shares of Momenta Pharmaceuticals set a new 52-week high after the company reported it entered into a definitive agreement with Johnson & Johnson to be acquired for $52.50 per share in cash.

more>

Pharmaceutical Firm Enrolls First US Patient in Phase 2b/3 Ifenprodil COVID-19 Trial (08/17/2020)

Algernon Pharmaceuticals reported it has enrolled the first U.S. patient in its multinational Phase 2b/3 human study of Ifenprodil for use in treatment of SARS-CoV-2.

more>

Canadian Biotech Advances Antibodies, Diagnostics Programs in Q2/20 (08/14/2020)

One highlight is ProMIS Neurosciences' development of a SARS CoV-2 antibody test.

more>

Telemedicine Firm Continues Expansion by Acquiring Majority Interest in Ontario Medical Clinic (08/14/2020)

The clinic will be integrated into the CloudMD EMR platform.

more>

Mesoblast Shares Rocket Higher as FDA Committee Votes in Favor of Remestemcel-L for Pediatric SR-aGVHD Patients (08/14/2020)

Shares of Mesoblast Ltd. traded 50% higher after the company reported that the U.S. FDA's Oncologic Drugs Advisory Committee voted nine to one in favor of remestemcel-L (RYONCIL™) for efficacy in children with steroid-refractory acute graft versus host disease.

more>

Life Sciences Firm Signs MOU for Phase 3 COVID-19 Study (08/14/2020)

Revive Therapeutics reported it signed a MOU with Attwill Medical Solutions Sterilflow to be a clinical packaging and distribution resource for its Phase 3 clinical trial of Bucillamine in COVID-19.

more>

Biotech Develops Oral Film Strips for Psychedelic Medicine Delivery (08/12/2020)

This development is a technical milestone for Revive Therapeutics and its drug delivery technology.

more>

Pennant Group Shares Fly 40% Higher on Q2 Earnings and Raised FY Adjusted EPS Guidance (08/12/2020)

Shares of The Pennant Group reached a new 52-week high after the company reported a 12.1% increase in Q2/20 revenue and raised FY/20 adjusted EPS guidance by 34.2%.

more>

Life Sciences Company Registers First Non-Antibiotic Livestock Feed Additive Sale in Brazil (08/12/2020)

Avivagen Inc. reported it achieved its first sale of OxC-beta™ Livestock in Brazil, the world's third largest livestock feed market.

more>

Eyenovia Shares Look 38% Higher on Development Deal with Arctic Vision in Asia (08/11/2020)

Shares of Eyenovia Inc. set a new 52-week high after the firm reported it entered into an exclusive collaboration and license agreement with Arctic Vision to develop and market MicroPine and MicroLine in China and South Korea.

more>

Seres Therapeutics Shares Go Parabolic on Positive Topline Data from Phase 3 C.Diff Trial (08/10/2020)

Seres Therapeutics shares traded 350% higher setting a new 52-week high after the firm reported positive topline results from its SER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection.

more>

Is Summit's Ridinilazole a Threat to Acurx's Ibezapolstat in the C.difficile Space? (08/10/2020)

Dr. KSS, the founder and editor-in-chief of BioPub.co, compares the two drugs as potential treatments for C. difficile.

more>

$18.5 Billion Merger Could Mean Big Gains for These Five Tiny Telemedicine Stocks (08/10/2020)

Independent financial analyst Matt Badiali examines five small companies poised to profit as digital health becomes mainstream during the coronavirus pandemic.

more>

Pharmaceutical Firm Doses First Patient in Phase 2 IPF and Chronic Cough Trial (08/08/2020)

Algernon Pharmaceuticals reported that the first patient has been dosed in the Phase 2 human study of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.

more>

Biopharma Preparing to Initiate Phase 3 COVID-19 Trial (08/07/2020)

Revive Therapeutics is now "finalizing agreements and aligning resources to initiate the Phase 3 clinical trial in September."

more>

Denali Shares Rise 37% on Advancement of DNL151 into Late Stage Parkinson's Trials (08/06/2020)

Shares of Denali Therapeutics reached a new 52-week high after the company reported plans to advance DNL151 in two separate late stage Parkinson's disease clinical studies with its partner Biogen.

more>

US Immunology Firm Lands Government Contract, Raises Cash (08/05/2020)

These two CytoSorbents events are discussed in a Dawson James report.

more>

Tech Firm Explains Key Feature of its Contact Tracing Solution (08/05/2020)

Loop Insights' technology lacks the adoption challenges that app-based solutions face.

more>

Fulgent Genetics' Shares Reach New 52-Week High After Posting 105% Increase in Q2 Revenue (08/05/2020)

Shares of Fulgent Genetics traded 22% higher after the company reported it posted a record $17.1 million in Q2/20 revenue and completed a record 180,513 billable tests in the quarter.

more>

Mobile Health Tech Firm Joins with US Healthcare Group to Bring Care Platform to 50,000 Patients (08/04/2020)

Reliq Health Technologies reported it has entered into a new contract with Diversified Healthcare Partners to provide its iUGO Care platform to more than 50,000 patients in three U.S. states.

more>

Biopharma Gets FDA Approval for Phase 3 COVID-19 Trial (08/04/2020)

Revive Therapeutics' trial will test Bucillamine in patients with mild to moderate COVID-19.

more>

Ten Good Reasons to Invest Now Pre-Market in Acurx Pharmaceuticals (08/03/2020)

Dr. KSS, the founder and editor-in-chief of BioPub.co, provides his investment thesis for a company that is promulgating the first new class of antibiotics in 30 years.

more>

More Archives

2020Sep Aug Jul Jun May Apr Mar Feb Jan

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2018Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2017Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes